U.S. Markets close in 5 hrs 1 mins

Rigel Pharmaceuticals, Inc. (RIGL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.325-0.045 (-1.899%)
As of 10:58AM EDT. Market open.
People also watch
ARRYPGNXPTIESPPINBIX
Full screen
Previous Close2.370
Open2.330
Bid2.310 x 8600
Ask2.320 x 1800
Day's Range2.280 - 2.350
52 Week Range1.940 - 4.380
Volume490,683
Avg. Volume687,703
Market Cap289.21M
Beta1.25
PE Ratio (TTM)-3.44
EPS (TTM)-0.68
Earnings DateOct 30, 2017 - Nov 3, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.25
Trade prices are not sourced from all markets
  • Rigel to Present at Cantor Fitzgerald Global Healthcare Conference
    PR Newswire6 days ago

    Rigel to Present at Cantor Fitzgerald Global Healthcare Conference

    SOUTH SAN FRANCISCO, Calif. , Sept. 19, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company's president and chief executive officer, is scheduled ...

  • Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : September 1, 2017
    Capital Cube24 days ago

    Rigel Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : RIGL-US : September 1, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Rigel Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish ... Read more (Read more...)

  • Rigel Welcomes Brian Kotzin, M.D. to Board of Directors
    PR Newswirelast month

    Rigel Welcomes Brian Kotzin, M.D. to Board of Directors

    SOUTH SAN FRANCISCO, Calif., Aug. 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A well-respected former professor and clinical researcher, Dr. Kotzin brings to Rigel's board three decades of experience in the areas of immunology and inflammation. "We are excited to welcome Dr. Kotzin to our board, and we feel confident that his leadership will be of great value to Rigel," said Raul Rodriguez, president and chief executive officer of Rigel.